Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

NCT04511130 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
92
Enrollment
INDUSTRY
Sponsor class

Stopped Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.

Conditions

Interventions

Sponsor

Marker Therapeutics, Inc.